Managing Side Effects While Using Levitra

Vardenafil is primarily metabolized by CYP3A; lenacapavir is a moderate CYP3A inhibitor.

• Levitra does not cure erectile dysfunction; it manages symptoms.
• Combining Levitra with certain antibiotics or antifungals may alter its effectiveness.
• Always follow the healthcare provider’s instructions for dosage and timing.
• Levitra is usually taken without regard to meals, but high-fat meals may delay action.
• Patients should report any allergic reactions such as rash or swelling.
• Use with caution in patients already taking blood pressure medications.
• Men with history of stroke or heart attack should consult a doctor before use.
• Levitra’s labeling includes warnings about potential side effects and interactions.

Lenvatinib: (Major) Concomitant use of vardenafil and lenvatinib increases the risk of QT/QTc prolongation and torsade de pointes (TdP).

Conditions treated by Levitra and Cialis

Fluvoxamine: (Major) Do not use vardenafil orally disintegrating tablets with fluvoxamine due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; fluvoxamine is a moderate CYP3A4 inhibitor. There may also be an increased risk for QT prolongation and torsade de pointes (TdP) during coadministration. Cases of QT prolongation and TdP have been reported during postmarketing use of fluvoxamine. Both therapeutic and supratherapeutic doses of vardenafil can produce an increase in the QTc interval.

How Levitra works:

Fosamprenavir: (Major) Do not use vardenafil orally disintegrating tablets with fosamprenavir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A; fosamprenavir is a moderate CYP3A inhibitor. Foscarnet: (Major) Concomitant use of vardenafil and foscarnet increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Fostemsavir: (Moderate) Concomitant use of vardenafil and fostemsavir may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. The degree of QT prolongation associated with fostemsavir is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 4 times the recommended daily dose.

Does Levitra have fewer side effects than Viagra?

Gemifloxacin: (Moderate) Concomitant use of vardenafil and gemifloxacin may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Gemtuzumab Ozogamicin: (Moderate) Concomitant use of vardenafil and gemtuzumab ozogamicin may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Gilteritinib: (Moderate) Concomitant use of vardenafil and gilteritinib may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Glasdegib: (Major) Concomitant use of vardenafil and glasdegib increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Goserelin: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., goserelin) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Letermovir: (Major) Do not use vardenafil orally disintegrating tablets with letermovir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; letermovir is a moderate CYP3A4 inhibitor.

Leuprolide: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., leuprolide) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monit oring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP.

How do these drugs work?

Granisetron: (Moderate) Concomitant use of vardenafil and granisetron may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Grapefruit juice: (Major) Grapefruit and grapefruit juice should be avoided during treatment with vardenafil orally disintegrating tablets due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; grapefruit juice is a moderate best price on levitra CYP3A4 inhibitor. Guaifenesin; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Halogenated Anesthetics: (Major) Concomitant use of vardenafil and halogenated anesthetics increases the risk of QT/QTc prolongation and torsade de pointes (TdP).

Join the online physician networking revolution now

Haloperidol: (Moderate) Concomitant use of vardenafil and haloperidol may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. The intravenous route may carry a higher risk for haloperidol-induced QT/QTc prolongation than other routes of administration. Histrelin: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., histrelin) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Consistent with their known effects on the nitric oxide/cGMP pathway, concomitant use of phosphodiesterase inhibitors and nitrates can cause severe hypotension, syncope, or myocardial infarction. Deaths have been reported in men who were using sildenafil while taking nitrate or nitrite therapy for angina.

When to interrupt dosage

Hydroxychloroquine: (Major) Concomitant use of hydroxychloroquine and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Hydroxyzine: (Moderate) Concomitant use of vardenafil and hydroxyzine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Ibutilide: (Major) Concomitant use of vardenafil and ibutilide increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Idelalisib: (Major) Do not use vardenafil orally disintegrating tablets with idelalisib due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; idelalisib is a strong CYP3A4 inhibitor. Leuprolide; Norethindrone: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., leuprolide) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

• Levitra may cause visual disturbances such as blurred vision in rare cases.
• Men taking medication for prostate issues should discuss Levitra with a doctor.
• It is essential to inform a doctor of any underlying health conditions before use.
• Levitra does not protect against sexually transmitted infections.
• Alcohol can increase the risk of side effects such as dizziness when using Levitra.
• Sexual health education complements medication therapy for ED.
• Levitra's safety profile has been established through numerous clinical trials.
• Use Levitra as directed; misuse can lead to serious health complications.

Levofloxacin: (Moderate) Concomitant use of levofloxacin and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Drug interactions of Levitra vs. Viagra

Iloperidone: (Major) Concomitant use of vardenafil and iloperidone increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Imatinib: (Major) Do not use vardenafil orally disintegrating tablets with imatinib due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; imatinib is a moderate CYP3A4 inhibitor. Indinavir: (Major) Do not use vardenafil orally disintegrating tablets with indinavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is levitra order uk primarily metabolized by CYP3A4/5; indinavir is a strong CYP3A4 inhibitor.

Mild side effects

Inotuzumab Ozogamicin: (Major) Concomitant use of vardenafil and inotuzumab increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Isavuconazonium: (Major) Do not use vardenafil orally disintegrating tablets with isavuconazonium due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Itraconazole: (Major) Do not use vardenafil orally disintegrating tablets with itraconazole due to increased vardenafil exposure. Vardenafil is primarily metabolized by CYP3A4/5; itraconazole is a strong CYP3A4 inhibitor. If coadministration of itraconazole and vardenafil oral tablets is required, the maximum single vardenafil dose is 5 mg every 24 hours in patients receiving itraconazole 200 mg daily; for patients receiving itraconazole 400 mg daily, the maximum single vardenafil dose is 2.5 mg every 24 hours.

What is vardenafil used for?

In addition, both itraconazole and vardenafil have been associated with QT prolongation; coadministration may increase this risk. Ketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and vardenafil due to an increased risk for QT/QTc prolongation and torsade de pointes (TdP). Concomitant use may also increase the exposure of vardenafil, further increasing the risk for adverse effects, such as hypotension and syncope. If concomitant use of ketoconazole and vardenafil oral tablets is required, the maximum single vardenafil oral tablet dose is 5 mg every 24 hours for patients receiving ketoconazole 200 mg daily and 2.5 mg every 24 hours for patients receiving ketoconazole 400 mg daily. Do not use vardenafil orally disintegrating tablets (ODTs) with ketoconazole. Levoketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and vardenafil due to an increased risk for QT/QTc prolongation and torsade de pointes (TdP).

Secondary Outcome

Coadministration with ketoconazole increased the AUC of vardenafil by 10-fold. Lansoprazole; Amoxicillin; Clarithromycin: (Major) Do not use vardenafil orally disintegrating tablets with clarithromycin due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Lapatinib: (Moderate) Concomitant use of vardenafil and lapatinib may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) levitra 20 brand in some patients. Lefamulin: (Major) Coadministration of lefamulin tablets is contraindicated with vardenafil due to increased vardenafil exposure which may result in QT prolongation and torsade de pointes (TdP). Avoid use of lefamulin injection with vardenafil; however, if coadministration of lefamulin injection cannot be avoided, ECG monitoring is recommended during treatment.

How is vardenafil supplied (dosage forms)?

Vardenafil is a primary CYP3A4 substrate that is associated with QT prolongation. Both therapeutic and supratherapeutic doses of vardenafil can produce an increase in QTc interval. Lefamulin is a moderate CYP3A4 inhibitor that has a concentration-dependent QTc prolongation effect. Coadministration of vardenafil with another moderate CYP3A4 inhibitor increased the AUC of vardenafil by 4-fold. Lenacapavir: (Major) Do not use vardenafil orally disintegrating tablets with lenacapavir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Lithium: (Moderate) Concomitant use of vardenafil and lithium may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.